---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014329"
form_type: "8-K"
ticker: null
cik: "0001460602"
company_name: "Orgenesis Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-03T23:59:59.045142+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orgenesis subsidiary sells five OMPULs to Germfree for $8.34M, enters 10-year collaboration

## Summary
- Orgenesis Maryland sells five Octomera Mobile Processing Units & Labs (OMPULs) to Germfree for $8.34M.
- Germfree gets a worldwide royalty-free license to Orgenesis' Quality Management Systems Framework (OQMSF).
- Germfree will exclusively manufacture and distribute OMPULs for Orgenesis worldwide for 10 years.
- Each party pays the other a 15% commission on Net Sales of OMPULs/services when customer is introduced.
- Strategic Collaboration Committee with 3 members from each party to oversee joint marketing and sales pipeline.

## SEC filing metadata
- accession: 0001493152-24-014329
- form_type: 8-K
- cik: 0001460602
- company_name: Orgenesis Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460602/000149315224014329/0001493152-24-014329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460602/000149315224014329/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014329
- JSON: https://secwatch.observer/filing/0001493152-24-014329.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014329.txt

## Key facts
- Material Agreements
  Orgenesis Inc. entered into Asset Purchase and Strategic Collaboration Agreement with Griffin Fund 3 BIDCO, Inc., ("Germfree") valued at aggregate purchase price of $8,340,000 (effective 2024-04-05).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Griffin Fund 3 BIDCO, Inc., ("Germfree")
  - Value: aggregate purchase price of $8,340,000
  - Effective: 2024-04-05
  source text: On April 5, 2024, Orgenesis Maryland LLC (“Orgenesis Maryland”), a wholly-owned subsidiary of Orgenesis Inc., entered into an Asset Purchase and Strategic Collaboration Agreement (the “Purchase Agreement”) with Griffin Fund 3 BIDCO, Inc., (“Germfree"), for the sale by Orgenesis Maryland of five Octomera Mobile Processing Units and Labs (“OMPULs”) to Germfree
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315224014329/0001493152-24-014329-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.